racemetirosine has been researched along with Adenocarcinoma, Basal Cell in 2 studies
alpha-Methyltyrosine: An inhibitor of the enzyme TYROSINE 3-MONOOXYGENASE, and consequently of the synthesis of catecholamines. It is used to control the symptoms of excessive sympathetic stimulation in patients with PHEOCHROMOCYTOMA. (Martindale, The Extra Pharmacopoeia, 30th ed)
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Kaira, K | 2 |
| Oriuchi, N | 2 |
| Shimizu, K | 2 |
| Ishikita, T | 1 |
| Higuchi, T | 1 |
| Imai, H | 1 |
| Yanagitani, N | 2 |
| Sunaga, N | 2 |
| Hisada, T | 1 |
| Ishizuka, T | 2 |
| Kanai, Y | 2 |
| Endou, H | 1 |
| Nakajima, T | 1 |
| Endo, K | 2 |
| Mori, M | 2 |
| Tominaga, H | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Correlation of Angiogenesis With 18F-FMT and 18F-FDG Uptake in Non-Small Cell Lung Cancer[NCT00671242] | 0 participants | Observational | Completed | ||||
| [NCT00464282] | 0 participants | Observational | Completed | ||||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
2 other studies available for racemetirosine and Adenocarcinoma, Basal Cell
| Article | Year |
|---|---|
Correlation of angiogenesis with 18F-FMT and 18F-FDG uptake in non-small cell lung cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; alpha-Methyltyrosine; Antigens, CD34; Carcinoma, Lar | 2009 |
18F-FMT uptake seen within primary cancer on PET helps predict outcome of non-small cell lung cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; alpha-Methyltyrosine; Analysis of Variance; Carcinom | 2009 |